JP2024519196A5 - - Google Patents

Info

Publication number
JP2024519196A5
JP2024519196A5 JP2023564487A JP2023564487A JP2024519196A5 JP 2024519196 A5 JP2024519196 A5 JP 2024519196A5 JP 2023564487 A JP2023564487 A JP 2023564487A JP 2023564487 A JP2023564487 A JP 2023564487A JP 2024519196 A5 JP2024519196 A5 JP 2024519196A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
amino acid
seq
composition according
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/060669 external-priority patent/WO2022223770A1/en
Publication of JP2024519196A publication Critical patent/JP2024519196A/ja
Publication of JP2024519196A5 publication Critical patent/JP2024519196A5/ja
Pending legal-status Critical Current

Links

JP2023564487A 2021-04-23 2022-04-22 皮膚エリテマトーデスの処置 Pending JP2024519196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178750P 2021-04-23 2021-04-23
US63/178,750 2021-04-23
PCT/EP2022/060669 WO2022223770A1 (en) 2021-04-23 2022-04-22 Treatment of cutaneous lupus erythematous

Publications (2)

Publication Number Publication Date
JP2024519196A JP2024519196A (ja) 2024-05-09
JP2024519196A5 true JP2024519196A5 (cg-RX-API-DMAC7.html) 2024-12-02

Family

ID=81850041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564487A Pending JP2024519196A (ja) 2021-04-23 2022-04-22 皮膚エリテマトーデスの処置

Country Status (11)

Country Link
US (1) US20250002589A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326322A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519196A (cg-RX-API-DMAC7.html)
KR (1) KR20240000557A (cg-RX-API-DMAC7.html)
CN (1) CN117222430A (cg-RX-API-DMAC7.html)
AU (1) AU2022261422A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021868A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216390A1 (cg-RX-API-DMAC7.html)
IL (1) IL307750A (cg-RX-API-DMAC7.html)
TW (1) TW202317617A (cg-RX-API-DMAC7.html)
WO (1) WO2022223770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113278071B (zh) * 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
GB202315831D0 (en) * 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN104603152A (zh) * 2012-06-13 2015-05-06 米迪缪尼有限公司 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
JP2023527054A (ja) * 2020-05-29 2023-06-26 アストラゼネカ・アクチエボラーグ I型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用

Similar Documents

Publication Publication Date Title
EP4114465B1 (en) Anti-ifnar1 dosing regime for subcutaneous injection
US20250051453A1 (en) Methods for treating bullous pemphigoid using fcrn antagonists
JP2024518735A5 (cg-RX-API-DMAC7.html)
JP2023546361A5 (cg-RX-API-DMAC7.html)
WO2023215769A1 (en) Il-13 antibodies for the treatment of atopic dermatitis
US20250002589A1 (en) Treatment of cutaneous lupus erythematous
JP2024543509A5 (cg-RX-API-DMAC7.html)
JP2024516886A5 (cg-RX-API-DMAC7.html)
JP2024527001A5 (cg-RX-API-DMAC7.html)
JP2024516886A (ja) 全身性エリテマトーデス患者における1型インターフェロン受容体阻害剤のステロイド節約
US20250326850A1 (en) Treatment of lupus
Choi et al. Suppressive effects of long-term treatment with inhaled steroids on hypothalamic-pituitary-adrenal axis in asthma
CN117337305A (zh) 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制
JP2020059749A (ja) Il−4rアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
EA052183B1 (ru) Лечение кожной красной волчанки
CN117677638A (zh) 狼疮的治疗
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection
Baba et al. Issues associated with stepwise management of bronchial asthma
RU2024118893A (ru) Комбинированная терапия, включающая антитело к il-23 и кортикостероид, для лечения псориаза
Divers Use of Corticosteroids in Equine Practice